Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.52 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.52 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5225799 | 0.90 | PARP1 (0.64) | PARP1CA1CA2PARP10PARP2 | |
| SCHEMBL475746 | 0.90 | CA1 (0.61) | CA1CA2USP2KDM4EALDH1A1 | |
| SCHEMBL10889230 | 0.90 | CA1 (0.58) | PARP1CA1CA2PARP10PARP2 | |
| Methyl 3,5-Dimethoxybenzoate SCHEMBL204865 | 0.86 | CA1 (0.61) | CA1CA2KDM4EALDH1A1CA12 | |
| SCHEMBL894796 | 0.86 | PARP1 (0.64) | PARP1CA1CA2PARP10PARP2 | |
| SCHEMBL18938219 | 0.82 | ATM (0.52) | PARP1CA1CA2USP2KDM4E | |
| SCHEMBL11264625 | 0.82 | CA1 (0.53) | CA1CA2USP2KDM4EALDH1A1 | |
| SCHEMBL10600019 | 0.82 | CA12 (0.50) | CA1CA2USP2KDM4EALDH1A1 | |
| SCHEMBL56890 | 0.82 | KDM4E (0.55) | CA1CA2USP2KDM4EALDH1A1 | |
| SCHEMBL20963871 | 0.82 | KDM4E (0.48) | PARP1CA1CA2USP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120087896-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE IN BIOASSAYS | PTC THERAPEUTICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-8101641-B2 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080139632-A1 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. | 2008-06-12 | — | — | US | disclosed |
| US-7074809-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| EP-1581525-A2 | COMPOUNDS HAVING AN ACTIVITY AT METABOTROPIC GLUTAMATE RECEPTORS | AstraZeneca AB (SE) | 2005-10-05 | — | — | EP | disclosed |
| US-20040106607-A1 | New compounds | ASTRAZENECA AB AND NPS PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
| WO-2004014902-A2 | COMPOUNDS HAVING AN ACTIVITY AT METABOTROPIC GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139632-A1 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | UPF1, RIOX2, RNMT | PARP1 2910/4885CA1 4634/4885CA2 4369/4885 |
| US-20040106607-A1 | New compounds | MTX1, MLX, TPX2 | PARP1 374/4885CA1 3796/4885CA2 3267/4885 |
| US-20120087896-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE IN BIOASSAYS | UPF1, RIOX2, RNGTT | PARP1 3261/4885CA1 3773/4885CA2 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.